Genentech: Aviv Regev
Aviv Regev will join Genentech as head of research and early development, effective August 1. She will replace Michael Varney, who will retire from his post at the end of July, and will also join Genentech's enlarged corporate executive committee. Regev is currently faculty chair, core institute member, and a member of the executive leadership team at the Broad Institute, as well as a professor of biology at the Massachusetts Institute of Technology and a Howard Hughes Medical Institute investigator. Prior to that, she was a Bauer fellow at the Center for Genomics Research at Harvard University. Regev holds a PhD in computational biology and a master of science degree from Tel Aviv University.
Seer: Omead Ostadan
Omead Ostadan will join Redwood City, California-based proteomics firm Seer as president and chief operating officer, effective June 29. He will also join the company's board of directors. Ostadan is currently chief product and marketing officer and a member of the executive management team of Illumina. He joined Illumina in 2007 as VP of marketing after the firm acquired Solexa, where he served in the same position. Prior to that, he held various marketing roles at Applied Biosystems. Ostadan holds a BS in biochemistry from the University of California, Davis, and an MBA from the Wharton School at the University of Pennsylvania.
Thermo Fisher Scientific: Garret Hampton
Garret Hampton has been appointed as president of the clinical next-generation sequencing and oncology business at Thermo Fisher Scientific. He joins the firm from Illumina, where he was senior VP of clinical genomics. Before that, he was VP and global head of oncology biomarker development and companion diagnostics at Genentech. Hampton holds a PhD in cancer genetics from the University of London and an undergraduate degree in natural sciences from Trinity College Dublin.
Roche: Fritz Gerber
Roche announced that former Group CEO and Chairman of the Board Fritz Gerber died at 92. Gerber served as group CEO from 1978 to 1998 and decentralized the company's structures. Under his leadership, Roche acquired a majority stake in Genentech, took over Boehringer Mannheim, and acquired PCR technology. After retiring as chairman in 2001, he remained an honorary chairman throughout the rest of his life.
Gerber was also on the board of IBM and created the Fritz Gerber Foundation for Gifted Young People.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.